Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has, for the second time, recommended the continuation without modification of the Company’s Phase III trial in Prader-Willi Syndrome (PWS) patients, DESTINY PWS. The outcome of this second planned meeting was based on the review of data from more than 50% of patients enrolled and treated. “We are pleased to again receive the DSMB’s recommendation to continue the Phase III trial as planned and without modification, which provides ongoing support of DCCR’s safety profile,” said Dr. Anish Bhatnagar, Chief Executive Officer of Soleno. “Enrollment in DESTINY PWS remains on track for the availability of top-line data in the first half of 2020.” DESTINY PWS is a Phase III, randomized, double-blind, placebo-controlled study
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.MarketBeat
- Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $73.00. They now have an "outperform" rating on the stock.MarketBeat
SLNO
Earnings
- 11/6/24 - Miss
SLNO
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/6/24 - Form 8-K
- SLNO's page on the SEC website